Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Repligen Corp.

http://www.repligen.com

Latest From Repligen Corp.

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

Europe Approvals

UCB Acquires Belgian Gene Therapy Firm Handl

The Brussels-based company has leant on its local knowledge to snap up Leuven-headquartered biotech Handl and its proprietary AAV capsid technology platform.

M & A Gene Therapy

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.

Deals Business Strategies

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

ASCO Clinical Trials
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Atoll GmBH
    • C Technologies, Inc.
    • Novozymes Biopharma Sweden AB
    • TangenX Technology Corporation
UsernamePublicRestriction

Register